Olaratumab for the treatment of soft-tissue sarcoma

Future Oncol. 2017 Oct;13(24):2151-2157. doi: 10.2217/fon-2017-0210. Epub 2017 Jul 26.


The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options. In the first line setting, a number of randomized trials have shown no difference in overall survival between combination anthracycline schedules and single agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable soft tissue sarcoma. In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.

Keywords: PDGFR-α; olaratumab; sarcomas.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Molecular Targeted Therapy*
  • Sarcoma / diagnosis
  • Sarcoma / drug therapy*
  • Sarcoma / mortality
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • olaratumab